Related Experiment Videos
Preventing ptosis after botulinum treatment
1Smith-Kettlewell Eye Research Institute, San Francisco, California 94115, USA.
Ophthalmic Plastic and Reconstructive Surgery
|June 1, 1997
Summary
Human botulinum immune globulin (IG) effectively prevents or reduces ptosis, a side effect of botulinum toxin type A injections. Specific dosages and timing of IG administration demonstrated significant efficacy in blepharospasm patients.
Area of Science:
- Neurology
- Ophthalmology
- Immunology
Background:
- Blepharospasm is often treated with botulinum toxin type A injections.
- Ptosis (drooping eyelid) is a common side effect of these treatments.
- Current management strategies for toxin-induced ptosis are limited.
Purpose of the Study:
- To evaluate the efficacy of human botulinum immune globulin (IG) in preventing or reducing ptosis.
- To determine optimal dosage and timing for IG administration.
- To assess the safety of IG injections in blepharospasm patients.
Main Methods:
- 33 blepharospasm patients experiencing ptosis post-botulinum toxin type A injection were studied.
- 41 injections of human botulinum immune globulin (IG) were administered.
- Different IG dosages and injection timings relative to the toxin were tested.
Main Results:
- An IG dose of 3.2 x 10(-3) IU per unit of Botox blocked toxin effect when injected within 4 hours.
- Higher IG doses (1.6 x 10(-2) to 3.2 x 10(-2)) in the levator muscle reduced ptosis incidence from 37% in control eyes to 11% in treated eyes.
- No adverse effects, including orbital hemorrhage, were reported.
Conclusions:
- Human botulinum immune globulin (IG) is effective in preventing and treating ptosis caused by botulinum toxin type A.
- Specific IG dosages and timely administration can significantly mitigate this common side effect.
- IG represents a safe and promising therapeutic option for managing toxin-induced ptosis.